share_log

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global...

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global...

据报道,Evotec宣布管理董事会变更;克雷格·约翰斯顿博士将于2024年12月31日卸任首席运营官;公司表示,首席运营官的职能责任将内部分配到全球各地……
Benzinga ·  11/30 00:09

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global Operations Leadership Team Until A New Organizational Structure Is Designed And Announced In Line With The Strategic Review

如先前所报道,Evotec宣布管理委员会变更;首席运营官Craig Johnstone博士将于2024年12月31日正式辞职;公司表示,首席运营官职能的职责将在全球运营领导团队内部分配,直至设计并按战略审查宣布新组织结构。

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024

Craig Johnstone博士将于2024年12月31日辞去首席运营官职务

Distribution of responsibilities internally

内部责任分配

HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019.

德国汉堡/ACCESSWIRE/2024年11月29日/Evotec SE(法兰克福证券交易所:EVt,SDAX/TecDAX,TRQX:EVTd,纳斯达克:EVO)今天宣布其首席运营官Craig Johnstone博士将于2024年12月31日辞职并离开公司。Johnstone博士于2012年5月加入Evotec,担任药物发现与创新效率高级副总裁,并于2015年4月被任命为Evotec(法国)SAS的总裁及现场负责人。Johnstone博士于2017年1月被任命为全球整合药物发现负责人,并于2019年1月1日成为首席运营官及Evotec管理委员会成员。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发